Endocrinology Advisor3d
Gastrointestinal Adverse Events Mediate Some Tirzepatide-Associated Weight Loss
Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.
The Best Obesity Drugs Aren’t Even Here Yet
A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.
New York Post1mon
Ozempic 3.0? This drug causes the greatest weight loss — by far
“The investigators in the trials of the participants assigned to liraglutide and tirzepatide did not provide additional information about the causes of deaths and their relation to the trial ...
technologynetworks3d
Weight Loss and Diabetes Drugs: What’s the Latest Research?
A recent Phase 3 trial published in Nature Medicine found that ... In the SURMOUNT-4 study – also sponsored by drugmaker Eli Lilly – participants who stopped taking tirzepatide regained much of their ...
Outsourcing-pharma8d
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Healio9d
About 31% of weight lost by adults during GLP-1 therapy comes from lean mass
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.